MX2022002244A - Metodo para identificar respondedores a degradantes de smarca2/4. - Google Patents
Metodo para identificar respondedores a degradantes de smarca2/4.Info
- Publication number
- MX2022002244A MX2022002244A MX2022002244A MX2022002244A MX2022002244A MX 2022002244 A MX2022002244 A MX 2022002244A MX 2022002244 A MX2022002244 A MX 2022002244A MX 2022002244 A MX2022002244 A MX 2022002244A MX 2022002244 A MX2022002244 A MX 2022002244A
- Authority
- MX
- Mexico
- Prior art keywords
- smarca2
- degraders
- responders
- identifying responders
- present
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a un método para tratar una enfermedad o trastorno con al menos un degradante de SMARCA2/4 en un sujeto que es respondedor a tal tratamiento, basándose en la presencia de alteraciones específicas de tumores descritas en la presente. La presente invención también proporciona los métodos para el tratamiento de cáncer de próstata en los sujetos que sea probable que respondan al tratamiento con degradantes de SMARCA2/4.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201941036639 | 2019-09-12 | ||
PCT/IB2020/058449 WO2021048799A1 (en) | 2019-09-12 | 2020-09-11 | Method for identifying responders to smarca2/4 degraders |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022002244A true MX2022002244A (es) | 2022-03-22 |
Family
ID=72840577
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022002244A MX2022002244A (es) | 2019-09-12 | 2020-09-11 | Metodo para identificar respondedores a degradantes de smarca2/4. |
Country Status (11)
Country | Link |
---|---|
US (2) | US11865114B2 (es) |
EP (1) | EP4028557A1 (es) |
JP (1) | JP2022547530A (es) |
KR (1) | KR20220061974A (es) |
CN (1) | CN114375192A (es) |
AU (1) | AU2020345178A1 (es) |
BR (1) | BR112022004573A2 (es) |
CA (1) | CA3150354A1 (es) |
IL (1) | IL291252A (es) |
MX (1) | MX2022002244A (es) |
WO (1) | WO2021048799A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11202104495YA (en) * | 2018-04-26 | 2021-05-28 | Aurigene Discovery Tech Ltd | Pyridazine derivatives as smarca2/4 degraders |
CN114599428A (zh) * | 2019-10-28 | 2022-06-07 | 豪夫迈·罗氏有限公司 | 双功能化合物 |
IL305956A (en) * | 2021-03-31 | 2023-11-01 | Duke Street Bio Ltd | Pharmaceutical material |
CN115611881A (zh) * | 2021-07-13 | 2023-01-17 | 复旦大学 | 一种合成新型vhl配体4-f-vh032的方法 |
KR20240046498A (ko) | 2021-08-09 | 2024-04-09 | 제넨테크, 인크. | Brm의 조절에 사용하기 위한 페놀 유도체 |
WO2023022218A1 (ja) * | 2021-08-20 | 2023-02-23 | 学校法人獨協学園獨協医科大学 | 線維腺腫と葉状腫瘍の鑑別方法 |
WO2023129506A1 (en) * | 2021-12-28 | 2023-07-06 | Board Of Regents, The University Of Texas System | Potent and selective smarca2 degrading chimeric molecules as cancer therapeutics |
WO2024002375A1 (zh) * | 2022-06-30 | 2024-01-04 | 甘李药业股份有限公司 | 一种用作smarca2/4抑制剂的化合物及其应用 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3062106B1 (en) | 2008-04-16 | 2020-11-11 | The Johns Hopkins University | Method for determining androgen receptor variants in prostate cancer |
US8133724B2 (en) | 2008-09-17 | 2012-03-13 | University Of Maryland, Baltimore | Human androgen receptor alternative splice variants as biomarkers and therapeutic targets |
CA2791244A1 (en) | 2010-03-08 | 2011-09-15 | Regents Of The University Of Minnesota | Androgen receptor isoforms and methods |
WO2014150751A2 (en) * | 2013-03-15 | 2014-09-25 | Novartis Ag | Biomarkers associated with brm inhibition |
JPWO2015005473A1 (ja) * | 2013-07-12 | 2017-03-02 | 国立研究開発法人国立がん研究センター | がんの治療への応答性を予測する方法 |
MA41598A (fr) | 2015-02-25 | 2018-01-02 | Constellation Pharmaceuticals Inc | Composés thérapeutiques de pyridazine et leurs utilisations |
US10772962B2 (en) | 2015-08-19 | 2020-09-15 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
ES2858151T3 (es) | 2016-05-20 | 2021-09-29 | Hoffmann La Roche | Conjugados de PROTAC-anticuerpo y procedimientos de uso |
KR20190140438A (ko) | 2017-02-28 | 2019-12-19 | 에피자임, 인코포레이티드 | 암 치료를 위한 smarca2의 저해 |
GB201714827D0 (en) | 2017-09-14 | 2017-11-01 | Nuclera Nucleics Ltd | Novel use |
SG11202104495YA (en) * | 2018-04-26 | 2021-05-28 | Aurigene Discovery Tech Ltd | Pyridazine derivatives as smarca2/4 degraders |
-
2020
- 2020-09-11 EP EP20790048.1A patent/EP4028557A1/en active Pending
- 2020-09-11 BR BR112022004573A patent/BR112022004573A2/pt unknown
- 2020-09-11 AU AU2020345178A patent/AU2020345178A1/en active Pending
- 2020-09-11 MX MX2022002244A patent/MX2022002244A/es unknown
- 2020-09-11 CN CN202080063910.8A patent/CN114375192A/zh active Pending
- 2020-09-11 WO PCT/IB2020/058449 patent/WO2021048799A1/en active Application Filing
- 2020-09-11 KR KR1020227007923A patent/KR20220061974A/ko unknown
- 2020-09-11 US US17/018,811 patent/US11865114B2/en active Active
- 2020-09-11 CA CA3150354A patent/CA3150354A1/en active Pending
- 2020-09-11 JP JP2022515603A patent/JP2022547530A/ja active Pending
-
2022
- 2022-03-09 IL IL291252A patent/IL291252A/en unknown
-
2024
- 2024-01-08 US US18/406,841 patent/US20240156814A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2022547530A (ja) | 2022-11-14 |
CA3150354A1 (en) | 2021-03-18 |
CN114375192A (zh) | 2022-04-19 |
US20210077486A1 (en) | 2021-03-18 |
AU2020345178A1 (en) | 2022-03-03 |
BR112022004573A2 (pt) | 2022-06-07 |
US20240156814A1 (en) | 2024-05-16 |
EP4028557A1 (en) | 2022-07-20 |
US11865114B2 (en) | 2024-01-09 |
WO2021048799A1 (en) | 2021-03-18 |
KR20220061974A (ko) | 2022-05-13 |
IL291252A (en) | 2022-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022002244A (es) | Metodo para identificar respondedores a degradantes de smarca2/4. | |
MX2019011858A (es) | Metodos para tratar el cancer con anticuerpos dirigidos a ps con agentes inmunooncologicos. | |
EA201792191A1 (ru) | Комбинированная терапия fgfr/pd-1 для лечения злокачественной опухоли | |
MX2019011148A (es) | Metodos de tratamiento. | |
MX2020008882A (es) | Dosificación para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1. | |
CY1118566T1 (el) | Διαγνωση με χρηση ιντερφερονης τυπου 1 | |
PH12019501116A1 (en) | Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20 | |
MX2021012977A (es) | Tratamiento del cáncer con tg02. | |
EA201890957A1 (ru) | Комбинированная терапия для лечения злокачественных опухолей | |
MX2020008906A (es) | Compuestos con actividad inductora de ferroptosis y métodos de uso de estos. | |
MX2018016183A (es) | Anticuerpos especificos del ligando 1 de muerte programada y metodos de uso de los mismos. | |
EA201992575A1 (ru) | Биомаркеры для терапии рака | |
WO2017062456A3 (en) | Biomarkers related to interleukin-33 (il-33)-mediated diseases and uses thereof | |
MX2019006331A (es) | Métodos para tratar el cáncer usando anticuerpos anti-pd-l1 y antiandrógenos. | |
WO2018064013A8 (en) | METHODS FOR TREATING CANCER WITH BAVITUXIMAB BASED ON LEVELS OF β2-GLYCOPROTEIN 1, AND ASSAYS THEREFOR | |
MX2020013535A (es) | Tratamiento de cáncer pulmonar de células no pequeñas (nsclc) en etapa iii y mitigación de las condiciones patológicas asociadas con el tratamiento. | |
MX2022005345A (es) | Terapia de combinación para el tratamiento de cáncer cerebral. | |
MX2021003262A (es) | Metodos de tratamiento. | |
MX2022016061A (es) | Degradadores de cinasa asociada al receptor interleucina-1 (irak) y usos de los mismos. | |
MX2022014180A (es) | Metodos, terapias y usos para tratar cancer. | |
MX2021003265A (es) | Metodos de tratamiento. | |
MX2021011799A (es) | Antagonistas de semaforina 4d para usarlos en la terapia contra el cancer. | |
WO2020176461A3 (en) | Methods and compositions for treating neuroendocrine prostate cancer | |
ZA201907369B (en) | Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment | |
EA202190226A1 (ru) | СПОСОБЫ ЛЕЧЕНИЯ HFpEF С ИСПОЛЬЗОВАНИЕМ ДАПАГЛИФЛОЗИНА И СОДЕРЖАЩИХ ЕГО КОМПОЗИЦИЙ |